Kyselina Acetylsalicylová Panpharma (Lysine Aspirin)

Lysine Aspirin acts on the cyclooxygenase pathway to provide antiplatelet and analgesic effects.

• Acute coronary syndrome: reduces platelet aggregation to lower risk of myocardial infarction.
• Percutaneous coronary intervention (PCI): maintains antiplatelet activity during and after the procedure.
• Severe pain or fever unresponsive to oral therapy: provides rapid analgesic and antipyretic effect.

• Lysine Aspirin irreversibly inhibits cyclooxygenase‑1 (COX‑1) enzymes in platelets, preventing the conversion of arachidonic acid to thromboxane A2. This blockade reduces platelet activation and aggregation, while also decreasing prostaglandin synthesis that contributes to inflammation and pain.

Lysine Aspirin may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Gastrointestinal irritation: dyspepsia, nausea, or abdominal discomfort.
• Minor bleeding: bruising, epistaxis, or gum bleeding.
• Headache: transient mild headache.
• Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

• Severe hemorrhage: gastrointestinal or intracranial bleeding.
• Anaphylactic reaction: rash, swelling, difficulty breathing.
• Reye syndrome: rare but potentially fatal in children.
• Hepatic dysfunction: elevated liver enzymes or jaundice.

When using Lysine Aspirin, several precautions should be observed to minimize risk.

• Bleeding risk: assess for active bleeding or coagulation disorders before administration.
• Hypersensitivity: avoid in patients with known aspirin or NSAID allergy.
• Asthma: use cautiously in aspirin‑exacerbated respiratory disease.
• Renal impairment: monitor kidney function in patients with reduced renal clearance.
• Concomitant anticoagulants: evaluate bleeding risk when combined with warfarin, heparin, or DOACs.
• Store at below 25°C: keep in original container, protect from moisture and light.

Lysine Aspirin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants (warfarin, heparin, DOACs): increased risk of severe bleeding.
• Other antiplatelet agents (clopidogrel, ticagrelor): additive antithrombotic effect leading to hemorrhage.
• SSRIs or SNRIs: heightened bleeding tendency.
• NSAIDs (ibuprofen, naproxen): competition for COX binding, reducing antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Corticosteroids: may potentiate gastrointestinal irritation.
• ACE inhibitors or ARBs: possible reduction in renal perfusion when combined with aspirin.
• Diuretics: monitor for renal function changes.
• Methotrexate: aspirin may decrease renal clearance of methotrexate.